GlassScriptPhysician profile
Olivia Keaton
NPI 1467072371
$1,370.20
in general payments reported to CMS, 2019-2025
12 companies · $566 in 2025
The $566 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $271 · 2024: $533 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,370.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $434.06 | 2023-2025 | Vraylar, Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $228.44 | 2023-2025 | Xifaxan |
| Exact Sciences Corporation | $154.78 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $145.44 | 2025 | Mounjaro, Zepbound |
| Shield Therapeutics INC | $96.01 | 2024 | |
| Pfizer INC. | $77.37 | 2023-2025 | |
| Novo Nordisk INC | $69.80 | 2024-2025 | Rybelsus, Ozempic |
| Phathom Pharmaceuticals, INC. | $62.01 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $40.59 | 2025 | Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $25.76 | 2023 | Rexulti |
| Amgen INC. | $20.44 | 2024 | Uplizna |
| Kowa Pharmaceuticals America, INC. | $15.50 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Keaton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.